The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Patient Derived Xenograft & PDX Models-Global Market Insights and Sales Trends 2024
Synopsis
Patient derived xenografts (PDX) are models of cancer where the tissue or cells from a patient's tumor are implanted into an immunodeficient or humanized mouse. PDX models are used to create an environment that allows for the natural growth of cancer, its monitoring, and corresponding treatment evaluations for the original patient.
The global Patient Derived Xenograft & PDX Models market size is expected to reach US$ 593.9 million by 2029, growing at a CAGR of 8.5% from 2023 to 2029. The market is mainly driven by the significant applications of Patient Derived Xenograft & PDX Models in various end use industries. The expanding demands from the Pre-clinical Drug Development and Basic Cancer Research and Biomarker Analysis, are propelling Patient Derived Xenograft & PDX Models market. Mice Models, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Rat Models segment is estimated at % CAGR for the next seven-year period.
Global top 5 manufacturers of patient-derived xenograft (PDX) models occupied for a share nearly 45 percent, key players are Crown Bioscience, Champions Oncology, Wuxi Apptec, EPO Berlin-Buch, and Oncodesign, etc. Geographically speaking, Asia Pacific holds the most of global market share, about 35%. North America holds about 30% of share, while Europe followed by nearly 20%. In terms of type, mouse model accounted for nearly 75%, and rat model accounted for a share of 25%,The application of patient-derived xenograft (PDX) models includes preclinical drug development and biomarker analysis. Preclinical drug development shares over 75%, while biomarker analysis shares about 20%.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Patient Derived Xenograft & PDX Models, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Patient Derived Xenograft & PDX Models market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Patient Derived Xenograft & PDX Models market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Patient Derived Xenograft & PDX Models sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Patient Derived Xenograft & PDX Models covered in this report include Crown Bioscience, The Jackson Laboratory, Champions Oncology, Charles River Laboratories, WuXi Apptec, Oncodesign, Horizon Discovery, Pharmatest Services and Hera Biolabs, etc.
The global Patient Derived Xenograft & PDX Models market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Crown Bioscience
The Jackson Laboratory
Champions Oncology
Charles River Laboratories
WuXi Apptec
Oncodesign
Horizon Discovery
Pharmatest Services
Hera Biolabs
EPO Berlin-Buch
Xentech
Urolead
Global Patient Derived Xenograft & PDX Models market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Patient Derived Xenograft & PDX Models market, Segment by Type:
Mice Models
Rat Models
Global Patient Derived Xenograft & PDX Models market, by Application
Pre-clinical Drug Development and Basic Cancer Research
Biomarker Analysis
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Patient Derived Xenograft & PDX Models companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Patient derived xenografts (PDX) are models of cancer where the tissue or cells from a patient's tumor are implanted into an immunodeficient or humanized mouse. PDX models are used to create an environment that allows for the natural growth of cancer, its monitoring, and corresponding treatment evaluations for the original patient.
The global Patient Derived Xenograft & PDX Models market size is expected to reach US$ 593.9 million by 2029, growing at a CAGR of 8.5% from 2023 to 2029. The market is mainly driven by the significant applications of Patient Derived Xenograft & PDX Models in various end use industries. The expanding demands from the Pre-clinical Drug Development and Basic Cancer Research and Biomarker Analysis, are propelling Patient Derived Xenograft & PDX Models market. Mice Models, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Rat Models segment is estimated at % CAGR for the next seven-year period.
Global top 5 manufacturers of patient-derived xenograft (PDX) models occupied for a share nearly 45 percent, key players are Crown Bioscience, Champions Oncology, Wuxi Apptec, EPO Berlin-Buch, and Oncodesign, etc. Geographically speaking, Asia Pacific holds the most of global market share, about 35%. North America holds about 30% of share, while Europe followed by nearly 20%. In terms of type, mouse model accounted for nearly 75%, and rat model accounted for a share of 25%,The application of patient-derived xenograft (PDX) models includes preclinical drug development and biomarker analysis. Preclinical drug development shares over 75%, while biomarker analysis shares about 20%.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Patient Derived Xenograft & PDX Models, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Patient Derived Xenograft & PDX Models market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Patient Derived Xenograft & PDX Models market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Patient Derived Xenograft & PDX Models sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Patient Derived Xenograft & PDX Models covered in this report include Crown Bioscience, The Jackson Laboratory, Champions Oncology, Charles River Laboratories, WuXi Apptec, Oncodesign, Horizon Discovery, Pharmatest Services and Hera Biolabs, etc.
The global Patient Derived Xenograft & PDX Models market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Crown Bioscience
The Jackson Laboratory
Champions Oncology
Charles River Laboratories
WuXi Apptec
Oncodesign
Horizon Discovery
Pharmatest Services
Hera Biolabs
EPO Berlin-Buch
Xentech
Urolead
Global Patient Derived Xenograft & PDX Models market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Patient Derived Xenograft & PDX Models market, Segment by Type:
Mice Models
Rat Models
Global Patient Derived Xenograft & PDX Models market, by Application
Pre-clinical Drug Development and Basic Cancer Research
Biomarker Analysis
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Patient Derived Xenograft & PDX Models companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Patient Derived Xenograft & PDX Models
1.1 Patient Derived Xenograft & PDX Models Market Overview
1.1.1 Patient Derived Xenograft & PDX Models Product Scope
1.1.2 Patient Derived Xenograft & PDX Models Market Status and Outlook
1.2 Global Patient Derived Xenograft & PDX Models Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Patient Derived Xenograft & PDX Models Market Size by Region (2018-2029)
1.4 Global Patient Derived Xenograft & PDX Models Historic Market Size by Region (2018-2023)
1.5 Global Patient Derived Xenograft & PDX Models Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Patient Derived Xenograft & PDX Models Market Size (2018-2029)
1.6.1 North America Patient Derived Xenograft & PDX Models Market Size (2018-2029)
1.6.2 Europe Patient Derived Xenograft & PDX Models Market Size (2018-2029)
1.6.3 Asia-Pacific Patient Derived Xenograft & PDX Models Market Size (2018-2029)
1.6.4 Latin America Patient Derived Xenograft & PDX Models Market Size (2018-2029)
1.6.5 Middle East & Africa Patient Derived Xenograft & PDX Models Market Size (2018-2029)
2 Patient Derived Xenograft & PDX Models Market by Type
2.1 Introduction
2.1.1 Mice Models
2.1.2 Rat Models
2.2 Global Patient Derived Xenograft & PDX Models Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Patient Derived Xenograft & PDX Models Historic Market Size by Type (2018-2023)
2.2.2 Global Patient Derived Xenograft & PDX Models Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Patient Derived Xenograft & PDX Models Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Patient Derived Xenograft & PDX Models Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Patient Derived Xenograft & PDX Models Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Patient Derived Xenograft & PDX Models Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Patient Derived Xenograft & PDX Models Revenue Breakdown by Type (2018-2029)
3 Patient Derived Xenograft & PDX Models Market Overview by Application
3.1 Introduction
3.1.1 Pre-clinical Drug Development and Basic Cancer Research
3.1.2 Biomarker Analysis
3.2 Global Patient Derived Xenograft & PDX Models Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Patient Derived Xenograft & PDX Models Historic Market Size by Application (2018-2023)
3.2.2 Global Patient Derived Xenograft & PDX Models Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Patient Derived Xenograft & PDX Models Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Patient Derived Xenograft & PDX Models Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Patient Derived Xenograft & PDX Models Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Patient Derived Xenograft & PDX Models Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Patient Derived Xenograft & PDX Models Revenue Breakdown by Application (2018-2029)
4 Patient Derived Xenograft & PDX Models Competition Analysis by Players
4.1 Global Patient Derived Xenograft & PDX Models Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Patient Derived Xenograft & PDX Models as of 2022)
4.3 Date of Key Players Enter into Patient Derived Xenograft & PDX Models Market
4.4 Global Top Players Patient Derived Xenograft & PDX Models Headquarters and Area Served
4.5 Key Players Patient Derived Xenograft & PDX Models Product Solution and Service
4.6 Competitive Status
4.6.1 Patient Derived Xenograft & PDX Models Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Crown Bioscience
5.1.1 Crown Bioscience Profile
5.1.2 Crown Bioscience Main Business
5.1.3 Crown Bioscience Patient Derived Xenograft & PDX Models Products, Services and Solutions
5.1.4 Crown Bioscience Patient Derived Xenograft & PDX Models Revenue (US$ Million) & (2018-2023)
5.1.5 Crown Bioscience Recent Developments
5.2 The Jackson Laboratory
5.2.1 The Jackson Laboratory Profile
5.2.2 The Jackson Laboratory Main Business
5.2.3 The Jackson Laboratory Patient Derived Xenograft & PDX Models Products, Services and Solutions
5.2.4 The Jackson Laboratory Patient Derived Xenograft & PDX Models Revenue (US$ Million) & (2018-2023)
5.2.5 The Jackson Laboratory Recent Developments
5.3 Champions Oncology
5.3.1 Champions Oncology Profile
5.3.2 Champions Oncology Main Business
5.3.3 Champions Oncology Patient Derived Xenograft & PDX Models Products, Services and Solutions
5.3.4 Champions Oncology Patient Derived Xenograft & PDX Models Revenue (US$ Million) & (2018-2023)
5.3.5 Charles River Laboratories Recent Developments
5.4 Charles River Laboratories
5.4.1 Charles River Laboratories Profile
5.4.2 Charles River Laboratories Main Business
5.4.3 Charles River Laboratories Patient Derived Xenograft & PDX Models Products, Services and Solutions
5.4.4 Charles River Laboratories Patient Derived Xenograft & PDX Models Revenue (US$ Million) & (2018-2023)
5.4.5 Charles River Laboratories Recent Developments
5.5 WuXi Apptec
5.5.1 WuXi Apptec Profile
5.5.2 WuXi Apptec Main Business
5.5.3 WuXi Apptec Patient Derived Xenograft & PDX Models Products, Services and Solutions
5.5.4 WuXi Apptec Patient Derived Xenograft & PDX Models Revenue (US$ Million) & (2018-2023)
5.5.5 WuXi Apptec Recent Developments
5.6 Oncodesign
5.6.1 Oncodesign Profile
5.6.2 Oncodesign Main Business
5.6.3 Oncodesign Patient Derived Xenograft & PDX Models Products, Services and Solutions
5.6.4 Oncodesign Patient Derived Xenograft & PDX Models Revenue (US$ Million) & (2018-2023)
5.6.5 Oncodesign Recent Developments
5.7 Horizon Discovery
5.7.1 Horizon Discovery Profile
5.7.2 Horizon Discovery Main Business
5.7.3 Horizon Discovery Patient Derived Xenograft & PDX Models Products, Services and Solutions
5.7.4 Horizon Discovery Patient Derived Xenograft & PDX Models Revenue (US$ Million) & (2018-2023)
5.7.5 Horizon Discovery Recent Developments
5.8 Pharmatest Services
5.8.1 Pharmatest Services Profile
5.8.2 Pharmatest Services Main Business
5.8.3 Pharmatest Services Patient Derived Xenograft & PDX Models Products, Services and Solutions
5.8.4 Pharmatest Services Patient Derived Xenograft & PDX Models Revenue (US$ Million) & (2018-2023)
5.8.5 Pharmatest Services Recent Developments
5.9 Hera Biolabs
5.9.1 Hera Biolabs Profile
5.9.2 Hera Biolabs Main Business
5.9.3 Hera Biolabs Patient Derived Xenograft & PDX Models Products, Services and Solutions
5.9.4 Hera Biolabs Patient Derived Xenograft & PDX Models Revenue (US$ Million) & (2018-2023)
5.9.5 Hera Biolabs Recent Developments
5.10 EPO Berlin-Buch
5.10.1 EPO Berlin-Buch Profile
5.10.2 EPO Berlin-Buch Main Business
5.10.3 EPO Berlin-Buch Patient Derived Xenograft & PDX Models Products, Services and Solutions
5.10.4 EPO Berlin-Buch Patient Derived Xenograft & PDX Models Revenue (US$ Million) & (2018-2023)
5.10.5 EPO Berlin-Buch Recent Developments
5.11 Xentech
5.11.1 Xentech Profile
5.11.2 Xentech Main Business
5.11.3 Xentech Patient Derived Xenograft & PDX Models Products, Services and Solutions
5.11.4 Xentech Patient Derived Xenograft & PDX Models Revenue (US$ Million) & (2018-2023)
5.11.5 Xentech Recent Developments
5.12 Urolead
5.12.1 Urolead Profile
5.12.2 Urolead Main Business
5.12.3 Urolead Patient Derived Xenograft & PDX Models Products, Services and Solutions
5.12.4 Urolead Patient Derived Xenograft & PDX Models Revenue (US$ Million) & (2018-2023)
5.12.5 Urolead Recent Developments
6 North America
6.1 North America Patient Derived Xenograft & PDX Models Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Patient Derived Xenograft & PDX Models Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Patient Derived Xenograft & PDX Models Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Patient Derived Xenograft & PDX Models Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Patient Derived Xenograft & PDX Models Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Patient Derived Xenograft & PDX Models Market Dynamics
11.1 Patient Derived Xenograft & PDX Models Industry Trends
11.2 Patient Derived Xenograft & PDX Models Market Drivers
11.3 Patient Derived Xenograft & PDX Models Market Challenges
11.4 Patient Derived Xenograft & PDX Models Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
